刘庄教授课题组与威斯康辛大学Weibo Cai教授课题组合作在ACS Nano上发表论文

发布时间:2012-03-01访问量:46设置

题目:

In Vivo Targeting and Imaging of Tumor Vasculature with Radiolabeled, Antibody-Conjugated Nanographene

作者:

Hao Hong,?,# Kai Yang,?,# Yin Zhang,§ Jonathan W. Engle,§ Liangzhu Feng,? Yunan Yang,? Tapas R. Nayak,? Shreya Goel,^ Jero Bean,? Charles P. Theuer,) Todd E. Barnhart,§ Zhuang Liu,?,* and Weibo Cai?,§,z,*

单位:

?Department of Radiology, University of Wisconsin;Madison, Madison, Wisconsin 53706, United States

? Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Institute of Functional Nano and Soft Materials Laboratory (FUNSOM), Soochow University, Suzhou, Jiangsu, China

§ Department of Medical Physics, University of Wisconsin;Madison, Madison, Wisconsin 53706, United States

^ Centre of Nanotechnology, Indian Institute of Technology, Roorkee, India

) TRACON Pharmaceuticals, Inc., San Diego, California, Unites States

z University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53792, United States

# These authors contributed equally to this work

摘要:

Herein we demonstrate that nanographene can be specifically directed to the tumor neovasculature in vivo through targeting of CD105 (i.e., endoglin), a vascular marker for tumor angiogenesis. The covalently functionalized nanographene oxide (GO) exhibited excellent stability and target specificity. Pharmacokinetics and tumor targeting efficacy of the GO conjugates were investigated with serial noninvasive positron emission tomography imaging and biodistribution studies, which were validated by in vitro, in vivo, and ex vivo experiments. The incorporation of an active targeting ligand (TRC105, a monoclonal antibody that binds to CD105) led to significantly improved tumor uptake of functionalized GO, which was specific for the neovasculature with little extravasation, warranting future investigation of these GO conjugates for cancer-targeted drug delivery and/or photothermal therapy to enhance therapeutic efficacy. Since poor extravasation is a major hurdle for nanomaterial-based tumor targeting in vivo, this study also establishes CD105 as a promising vascular target for future cancer nanomedicine.

影响因子:

9.865

分区情况:

1



责任编辑:向丹婷




返回原图
/


XML 地图 | Sitemap 地图